EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC

Yuxiang Sun, Qinglin Wang, Pengcheng Zhu, Zhitong Li, Tongyan Liu, Rong Yin iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.71792 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yuxiang Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital…. Hauptthemen laut MEDLINE: Brain Neoplasms, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China, Yishan Research Project of Jiangsu Cancer Hospital, Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Innovation Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastasis (BM) is a leading cause of cancer‐related mortality, particularly in patients with lung cancer. Traditional diagnostic methods, such as tissue biopsies, are often impractical, and there are currently no reliable biomarkers for early detection in clinical practice. In this context, liquid biopsy has emerged as a valuable non‐invasive diagnostic tool for cancer patients with BM. This review summarizes the advantages and current limitations (such as the low sensitivity in early‐stage disease and the potential for false positives from non‐cancer sources) of liquid biopsy samples, specifically focusing on peripheral blood and cerebrospinal fluid (CSF). We discuss key biomarkers, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor‐derived platelets (TEPs), and current technologies for their detection, highlighting their potential clinical applications. Additionally, we explore the role of liquid biopsy in patients with epidermal growth factor receptor‐mutated ( EGFR‐ mutant) non‐small cell lung cancer (NSCLC), a group that experiences a high incidence of BM. Finally, we address emerging biomarkers and innovative detection methods, offering recommendations for enhancing the application of liquid biopsy in clinical settings. Our review aims to underscore the significance of liquid biopsy in improving the detection and management of BM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsBiomarkers, TumorCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansLiquid BiopsyErbB ReceptorsMutationNeoplastic Cells, CirculatingCirculating Tumor DNA

Stichwörter der Autor:innen

EGFRNSCLCbrain metastasisliquid biopsy

Substanzen

Biomarkers, TumorErbB ReceptorsEGFR protein, humanCirculating Tumor DNA

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China.
  • The Fourth Clinical College of Nanjing Medical University, Nanjing, P.R. China.
  • Department of Science and Technology, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China.
  • Collaborative Innovation Center for Cancer Personalized Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, P.R. China.
  • Department of Thoracic Surgery, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P.R. China.

ORCID-Profile: Rong Yin

Förderung

  • National Science Foundation of China
  • Yishan Research Project of Jiangsu Cancer Hospital
  • Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Innovation Center
  • National Science and Technology Major Project
  • National Natural Science Foundation of China

Zitieren

APA

Sun, Y., Wang, Q., Zhu, P., Li, Z., Liu, T., & Yin, R. (2026). Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC. Cancer Medicine. https://doi.org/10.1002/cam4.71792

Vancouver

Sun Y, Wang Q, Zhu P, Li Z, Liu T, Yin R. Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC. Cancer Medicine. 2026. doi:10.1002/cam4.71792

BibTeX
@article{Sun2026,
  author = {Sun, Yuxiang and Wang, Qinglin and Zhu, Pengcheng and Li, Zhitong and Liu, Tongyan and Yin, Rong},
  title = {Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71792}
}
Kostenlos starten →